Epithalon
Epitalon, AEDG tetrapeptide
A synthetic tetrapeptide derived from a pineal extract. It is the compound most closely associated with the claim that telomerase activity and telomere length can be manipulated — a claim supported by small studies and enormous speculation.
- Category
- Longevity
- Half-life
- Very short
- Cycle length
- 10–20 day courses, often annual
- Level
- advanced
Overview
Epithalon was developed from epithalamin, a pineal-gland extract studied in the Soviet Union. The synthetic tetrapeptide was designed to reproduce its proposed effects on neuroendocrine regulation. In the longevity community it is almost always discussed in the context of telomeres, on the strength of a small number of studies in human cells and a handful of small clinical reports.
How it works
The proposed mechanism is induction of telomerase reverse transcriptase, the enzyme that maintains telomere length. Telomerase activation has been demonstrated in cultured human cells exposed to Epithalon. It is also proposed to influence pineal melatonin production and to normalise neuroendocrine function, which is the older, better-characterised line of research.
Reported benefits
- Telomerase activation demonstrated in human cell cultures
- Reported normalisation of melatonin rhythm
- Improved markers of immune function in small studies
- Reported improvements in sleep quality
Reported benefits describe what the published literature and user reports suggest — not a promise of outcome for any individual.
Dosing reference
Reported protocols use 5–10 mg per day subcutaneously or intramuscularly for ten to twenty days, sometimes repeated once or twice a year.
Protocols are short and infrequent by design — the logic being a pulse of telomerase activation rather than continuous exposure. There is no accepted human dosing standard.
Community-reported: 5–10 mg daily by injection for ten to twenty days, then a break of several months before repeating — a rhythm inherited from the original Russian research protocols rather than from human trials.
These figures are what people report using in public communities. They have not been studied, verified or checked against certificates of analysis, and they are not a recommendation, a prescription or a target to aim for.
Where the reported amounts come from
Amounts are reproduced for education only. Doses from trials cannot be assumed to suit anyone else, and community-reported amounts are frequently wrong. Self-administering unapproved compounds carries serious risk.
The research picture
The telomerase finding is real but modest: it comes from cell culture work and a small number of studies with limited participant numbers. The clinical longevity claims people make about Epithalon go far beyond anything the data supports. Telomere length is also a contested proxy for ageing, and some research suggests that sustained telomerase activation could in principle support unwanted cell proliferation. Treat headline claims here as hypothesis, not finding.
Preclinical & non-clinical data
A tetrapeptide studied in Russian research for telomerase activity and pineal regulation in cells and animals. The human trial literature is thin, old and rarely replicated outside that research tradition.
Non-clinical data comes from cells and animals unless stated otherwise. It answers whether a compound is worth studying in people — not whether it is safe or effective in them.
What users report
The telomerase angle made it popular, and the reports are correspondingly themed: better sleep, more vivid dreams and a general sense of wellbeing across ten- to twenty-day courses that people repeat two or three times a year. Users consistently describe the effect as subtle, and the more careful accounts note the obvious problem — nobody in these threads measures telomere length or telomerase activity, so the entire mechanism the compound is sold on goes unverified in the very reports used to recommend it.
Where these reports come from
These are unverified personal accounts collected from public sources. They are not evidence of effectiveness or safety, they have not been independently checked, and they are not a recommendation to use anything described.
Possible side effects
- Injection-site irritation
- Reported transient headache
- Reported fatigue in the days after a course
- Dizziness reported anecdotally
Safety notes
This is the compound on this site with the most theoretical long-term concern. Telomerase activation is a hallmark of most cancer cells, and deliberately inducing it outside of controlled clinical research is genuinely uncertain territory. Anyone with a personal or family history of cancer should treat this as off-limits. There is no long-term human safety data at all.
Stacking
Sometimes seen alongside NAD+ or other mitochondrial-directed compounds in longevity stacks, though the compounding of two poorly-evidenced interventions is worth thinking about carefully before it is done.
Related compounds
Ipamorelin
NNC 26-0161
Longevity
A selective growth-hormone secretagogue with a clean profile.
Elamipretide (SS-31)
SS-31 — mitochondria-targeted tetrapeptide
Longevity
Elegant mitochondrial biology, repeatedly disappointing trial endpoints.
Humanin
24-amino-acid mitochondrial-derived peptide; HNG is a synthetic analogue
Longevity
The mitochondrial peptide that protects cells in the dish — and is sold well beyond its evidence.